Meeting Materials

Abstract: Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). This randomized controlled trial evaluated the effectiveness and safety of a novel DTx for MDD as an adjunct to antidepressant treatment (ADT) monotherapy (NCT04770285).

A variety of multimodal treatments that can address the spectrum of MDD symptom domains and ongoing management challenges, including residual symptoms and treatment-emergent adverse effects (TEAEs) have emerged that may address unmet needs in MDD pharmacotherapy.

Abstract: Background: Caregivers play an important role in the lives of people with schizophrenia. This analysis aimed to understand the caregivers’ role and gain their perspective toward using long-acting injectable antipsychotics (LAI).

Abstract: Background: For patients with schizophrenia, long-acting injectable (LAI) antipsychotics can reduce relapse and hospitalization rates and improve adherence versus oral antipsychotics.

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion; Auvelity) is a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist approved for treating major depressive disorder (MDD) in adults.

Abstract: Parkinson's Disease (PD) psychosis poses major treatment challenges due to the delicate balance required between managing motor deficits and psychotic symptoms. Treating PD associated psychosis is complicated due to the etiology of the disease.

Abstract: Introduction: People with major depressive disorder (MDD) have impaired neuroplasticity. Antidepressant treatment and some nonpharmacological interventions can lead to changes in neuroplasticity that improve MDD symptoms.

Abstract: BACKGROUND: To generate real-world evidence of esketamine effectiveness for treatment resistant depression (TRD), this study assessed change in depressive symptoms after esketamine initiation in a large psychiatric practice based on Patient Health Questionnaire (PHQ-9) scores.

Abstract: Objective: Long-acting injectables (LAIs) may provide an advantage over daily oral antipsychotics (OAPs), but little real-world evidence exists in the Medicare population, which includes about half of US patients with schizophrenia.

Abstract: Objective: A prior integrated patient-level analysis revealed a significant benefit of implementing paliperidone palmitate (PP) versus oral antipsychotics (OAPs) earlier in the course of schizophrenia.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor for the treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)–related chorea.

Abstract: Rationale

Abstract: This research analyzes the outcomes of a federal training grant first awarded in 2017 by the Health Resources and Services Administration (HRSA) to address the shortage of behavioral health providers in the U.S.

Abstract: Introduction: A patient-digital therapeutic (DTx) bond (digital working alliance [DWA]) may be important for DTx success.

Abstract: Background: Individuals with major depressive disorder (MDD) with loss of interest and reduced activity respond poorly to serotonergic antidepressants.

Abstract: Background: Psychiatrists’ views on schizophrenia treatment goals and use of long-acting injectable antipsychotics (LAIs) vary widely.

Abstract: Background: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. In real-world settings, OLZ/SAM treatment may be associated with healthcare resource utilization (HCRU) reductions.

Abstract: Background: Benztropine may be prescribed off-label to patients with tardive dyskinesia (TD) to provide symptom relief; however, per benztropine prescribing information, it may aggravate TD symptoms.

Abstract: Background

Abstract: Background: Patient-reported outcomes (PROs) are important for assessing disease burden. Specific measures characterizing the multidimensional impact of tardive dyskinesia (TD) are lacking.

Abstract: Background: Despite the prevalence of major depressive disorder (MDD), little is known about the burden of anhedonia, a core MDD symptom associated with MDD severity, functional impairment, and poor prognosis.

Abstract: Nurse burnout continues to be a significant challenge in healthcare settings, impacting both the well-being of nurses and the quality of patient care.

Abstract: Background: The IMPACT-TD Patient Reported Outcome (IMPACT-TD PRO) scale is a newly developed patient questionnaire to assess the multidimensional impact of tardive dyskinesia (TD) on the patients’ quality of life.

Abstract: A 57-year-old female patient with a known history of left frontotemporal meningioma presented to the emergency room with visual and auditory hallucinations and hyper-religiosity.

Abstract: Schizophrenia, a chronic mental illness, requires long-term treatment with antipsychotics, where adherence is crucial for favorable clinical and economic outcomes. Adherence, however, is a multifaceted concept, not fully captured by a single measure.

Abstract: Objective: To describe the long-term efficacy of esketamine nasal spray (ESK) in adult patients (aged 18-64 years) with treatment-resistant depression (TRD) dosed according to US prescribing information, including an evaluation of early (day 8) and delayed (week 8) responders.

Abstract: Objective: To describe the long-term safety and efficacy of flexibly dosed esketamine nasal spray (ESK) in patients with treatment-resistant depression (TRD) from SUSTAIN-3 (NCT02782104).

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

Abstract: Background: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or bipolar II disorder (BD).

Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonists–most commonly antipsychotic drugs.

Abstract: Background: The IMPACT-TD scale is a newly developed clinical tool to assess the multidimensional impact of tardive dyskinesia (TD) on patients’ quality of life (QoL).

Abstract: Introduction: Obligate mirror alternating hemiprosopometamorphopsia has not heretofore been described. Such a case is presented.

Abstract: Anhedonia is a core feature of major depressive disorder (MDD). However, little is known about its related symptom burden and its impact on patients’ clinical trajectory.

Abstract: The patient is an 81-year-old female with a past medical history of dementia who presented to the hospital for a mechanical fall.

Abstract: Depression is a debilitating disorder, and it is expected to overtake cardiac illnesses as the top source of disease burden in 7 years. It is a psychiatric disorder that is diagnosed by using the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5).

Abstract: Background: Psychiatric nurses play a key role in schizophrenia treatment; their perceptions of long-acting injectable antipsychotics (LAIs) vary.

Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage.

Abstract: Introduction: AXS-05 (dextromethorphan-bupropion), a novel, oral, N-methyl-D-aspartate (NMDA) receptor antagonist and sigma-1 receptor agonist, gained approval from the US FDA in August 2022 for treating major depressive disorder (MDD) in adults.

Abstract: BACKGROUND: Real-world evidence of clinical benefits of esketamine nasal spray for treatment-resistant depression (TRD) is limited. This study used health insurance claims data augmented with Patient Health Questionnaire (PHQ-9) scores to address this gap in knowledge.

Abstract: Tardive dyskinesia (TD) is a persistent and potentially debilitating movement disorder associated with antipsychotic exposure.

Abstract: Purpose: To examine real-world incidence of esketamine nasal spray (ESK) treatment-emergent adverse events (TEAEs) of interest (i.e., actively solicited events of sedation, dissociation, and increased blood pressure [BP]) and serious adverse events (SAEs) in the US and determine whether

Abstract: Assessment of real-world outcomes associated with different antipsychotics helps inform treatment selection for patients with schizophrenia. This real-world study aimed to compare outcomes of patients with schizophrenia treated with once-monthly paliperidone palmitate (PP1M) vs.

Abstract: Background: Two phase 3 trials evaluating TV-46000 for schizophrenia enrolled patients aged 13–65 years. Adolescents aged 13–18 years and young adults aged 19–21 years who received TV-46000 in these studies are included in this safety analysis.

Abstract: Background: In the phase 3 KINECT®-HD (NCT04102579) study, valbenazine significantly improved chorea versus placebo in adults with Huntington’s disease (HD).

Abstract: Background: This analysis used pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from R064766 (a once-every-2-weeks [q2w] intramuscular long-acting injectable antipsychotic formulation of risperidone microspheres) to TV-46000 (a once-monthly [q

While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, including non-adherence, inadequate response, and/or medication-related adverse events.

Abstract: Objective: To describe characteristics of patients from a prospective observational study evaluating postpartum depression (PPD) care pathways.

Abstract: Abstract Background Neurological complications after covid-19 are well described. TMS plays a role in the treatment of this condition. However, the use of TMS in neurological complications following Covid-19 vaccination are not yet reported in the literature.

Abstract: Introduction: Less than half of patients receiving first-line antidepressant (ADT) treatment for major depressive disorder (MDD) achieve remission. When considering the next treatment strategy, healthcare professionals (HCPs) must assess benefits, risks, and other factors.

Abstract: Once-daily valbenazine is approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD).

Abstract: BACKGROUND: Durability of esketamine clinical benefits for treatment resistant depression (TRD) may correlate with treatment sessions completed and therapy persistence.

Abstract: PTSD is defined as a group of symptoms which include intrusive flashbacks and re-experiences of a traumatic event, avoidance of any trauma related stimuli, negative changes in moods and increased arousal and reactivity to one’s environment.

Abstract: Objective: To examine baseline and disease characteristics of patients with treatment-resistant depression (TRD) who achieved remission at week 8 with quetiapine extended release (QXR) or esketamine nasal spray (ESK) (both with an oral antidepressant) in ESCAPE-TRD (NCT04338321) to iden

Abstract: Our case involves a 64-year-old male with a past psychiatric history of schizoaffective disorder (bipolar type; on clozapine 400mg nightly) and who presented to the hospital for evaluation after a near syncopal episode and generalized weakness in the setting of 3-7 days of decreased ora

Abstract: Background: We and others surmise that clozapine-induced myocarditis may be more common now that Covid-19 virus is among us. Clozapine, Covid, and the mRNA vaccine used to fight the virus can all independently lead to myocarditis, a potentially fatal sequela.

Abstract: STARS-ADHD-Adolescents was a multicenter, single-arm trial conducted at 14 US research sites to evaluate objective attention functioning and ADHD symptoms and impairments after 4 weeks of AKL-T01 treatment in adolescents aged 13-17 years.

Abstract: Since March of 2020, the leukotriene receptor antagonist Montelukast has been recognized by the FDA to cause adverse neuropsychiatric events including rare cases of nightmares and somnambulism.

Abstract: Objective: To describe key characteristics and treatment patterns in patients with unresolved MDD symptoms by leveraging real-world data.

Abstract: Delirium is not a well-known adverse effect of Vivitrol. This report describes a rare case of delirium involving visual hallucinations and grandiose delusions associated with Vivitrol use that resolved after about 72 hours of being stabilized with lorazepam.

Abstract: Background: Physical manifestations of tardive dyskinesia (TD) impact daily activities and present a substantial psychosocial burden. This study was designed to survey differences in perception of TD impact among US-based patients and healthcare professionals (HCPs).

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are approved in the US for treatment of adults with tardive dyskinesia (TD).

Abstract: Treatment-resistant depression can be difficult to identify in the outpatient behavioral health setting due to a lack of clear diagnostic guidelines.

Abstract: Two patients with previous unsuccessful psychiatric treatment under went a neurophysiologic evaluation method that included EEG, QEEG and Loreta brain scans. Each patient's lab data directed counterintuitive medicinal treatment that has been successful for over 15 years.

Abstract: Fentanyl positivity grew by nearly 150% nationally from 2019 to 2022 and is now the most frequently detected drug in those analyzed with substance use disorder.

Abstract: Background: Effective and comprehensive treatment of tardive dyskinesia (TD) requires reducing patients’ abnormal involuntary movements while maintaining their psychiatric stability.

Abstract: Background: The substantial disease burden of schizophrenia may be accompanied by disparities in diagnosis and treatment, such as with the use of second-generation antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs).

Abstract: Background: Social determinants of health (eg, race/ethnicity, resources) impact quality of care for a number of chronic diseases.

Abstract: Background: TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative, copolymer-based drug delivery technology.

Abstract: Background: Major depressive disorder (MDD) is a debilitating disease for which there is an unmet need for rapid-acting treatments. Zuranolone is an investigational oral, once-daily, 14-day treatment for adults with MDD and PPD.

Abstract: Background: Schizophrenia requires long-term treatment with antipsychotics; however, poor adherence to antipsychotic treatment can result in increased healthcare resource utilization, placing a burden on the healthcare system.

Abstract: Background: Low adherence to antipsychotic medication following a hospital discharge among patients with schizophrenia can lead to a higher risk of relapse and greater health care utilization. Using real-world data from a U.S.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Valbenazine and deutetrabenazine (vesicular monoamine transporter 2 inhibitors) are indicated for treatment of adults with tardive dyskinesia (TD).

Abstract: Background: Although long-acting injectable antipsychotics (LAIs) improve adherence and reduce schizophrenia relapse rates, they remain underutilized in clinical practice.

Abstract: Background: Deutetrabenazine is a vesicular monoamine transporter type 2 inhibitor (VMAT2i) for treatment of adults with tardive dyskinesia (TD) and Huntington disease (HD)-related chorea.

Abstract: Background: Major depressive disorder (MDD) is a debilitating illness in which depressive symptoms may persist after antidepressant treatment. APA guidelines recommend clinicians modify treatment in patients who are non-responders to 4-8 weeks of treatment with the goal of remission.

<p>Abstract: Background: Upon approving esketamine nasal spray (ESK) in conjunction with an oral antidepressant for treatment-resistant depression in adults, the FDA required a Risk Evaluation and Mitigation Strategy (REMS) to mitigate the risks of serious adverse outcomes resulting from se

Abstract: Background: This post hoc analysis of SUSTAIN-2 (NCT02497287), an open-label, long-term safety and efficacy study of esketamine nasal spray (ESK), assessed sustained response (SR) to ESK in combination with an oral antidepressant (OAD) in adults with treatment-resistant depression (TRD)

Abstract: Objective: ESCAPE‑TRD (NCT04338321), a randomized, open-label, rater-blinded, trial demonstrated benefits for esketamine nasal spray (ESK) versus quetiapine extended release (QXR) for acute and maintenance treatment of adult patients, aged 18-64 years, with treatment-resistant depressio

Abstract: Background: Among patients with schizophrenia, nonadherence to oral antipsychotics increases relapse risk. Adherence may be improved with long-acting injectable (LAI) antipsychotics.

Abstract: OBJECTIVES: To evaluate total all-cause healthcare costs among US patients diagnosed with major depressive disorder (MDD) who failed first-line antidepressant treatment (ADT).

Abstract: Background: Treatment with long-acting injectable antipsychotics (LAIs) reduces relapses in schizophrenia; however, best practices for introducing and transitioning patients to LAIs, as well as how to navigate barriers to LAI initiation, vary among clinicians.

Abstract: Background: The phase 3 schizophrenia program for TV-46000, a long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone, included the RISE efficacy study (NCT03503318) and the SHINE long-term safety study (NCT03893825).

Abstract: Background: In 2020, approximately 14.2 million US adults suffered with serious mental illness.

Abstract: Background: Valbenazine is a highly selective vesicular monoamine transporter 2 inhibitor indicated for tardive dyskinesia (TD), a persistent and potentially debilitating movement disorder associated with prolonged antipsychotic exposure.

Abstract: OBJECTIVES: Evaluate clinical and economic outcomes of zuranolone, an investigational drug, versus standard-of-care (SOC) antidepressants in adult patients with major depressive disorder (MDD) to generate suggested value-based willingness-to-pay (WTP) ranges for zuranolone.

Abstract: Olanzapine is a second-generation antipsychotic with a well-established efficacy:safety profile. Since olanzapineís approval in 1996 for treatment of schizophrenia, more antipsychotic options have become available.

Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression.

Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and depressive episodes associated with bipolar I or II disorder.

Abstract: Objective: To evaluate improvements in items of the Montgomery-≈sberg Depression Rating Scale (MADRS) and Patient Health Questionnaire-9 (PHQ-9) over 4 weeks of esketamine nasal spray (ESK) monotherapy.

Abstract: Introduction: CT-152 is a prescription digital therapeutic for treating patients with major depressive disorder (MDD) as an adjunct to antidepressant medication. The durability of CT-152 beyond the clinical trial duration remains unknown.

Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD) that has shown benefit over sham on multiple clinician and participant-reported scales (NCT04770285).

Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD). In the Mirai trial (NCT04770285), CT-152 showed benefit over sham on multiple clinician and participant-reported scales.

Abstract: Introduction: CT-152 is a prescription digital therapeutic adjunct to antidepressant medication for patients with major depressive disorder (MDD).

Abstract: Background: The Phase 3 TRANSFORM-2 study (NCT02418585/Popova et al.Am J Psychiatry.2019;176[6]:428-438) evaluated the efficacy and safety of esketamine nasal spray and supported its approval for adults with treatment-resistant depression (TRD) in conjunction with an oral antidepressant

Abstract: Background: BI 1569912 is a selective negative allosteric modulator of NR2B subunit-containing NMDA receptors (NR2B NAM) in development for major depressive disorder (MDD).

Abstract: Objective: To evaluate the efficacy and safety of esketamine nasal spray (ESK) monotherapy in adults with treatment-resistant depression (TRD) from a multicenter study (NCT04599855).

Abstract: Background: In a pivotal study, the dextroamphetamine transdermal system (d-ATS) met primary and secondary efficacy endpoints for ADHD in children and adolescents. d-ATS efficacy among subgroups was investigated using ADHD-RS-IV total score.

Abstract: Goal: This project investigates how patients undergoing active treatment with a novel FDA-approved antidepressant, esketamine for treatment-resistant depression, can meaningfully enhance the ongoing education of healthcare professionals through their questions and insights.

Abstract: Major depressive disorder is the leading cause of disability worldwide. Almost a third of patients with major depression failed to achieve remission despite treatment with multiple antidepressants.

Abstract: Background: In the treatment of MDD, critical needs remain for improved patient outcomes through medications with novel mechanisms of action (MOA).

Abstract: Background:Lumateperone is FDA-approved to treat schizophrenia and bipolar depression.

Abstract: Introduction:

Abstract: Background: Lumateperone is FDA-approved to treat schizophrenia and bipolar depression.

Abstract: People treated for Major Depressive Disorder (MDD) exhibit varying levels of satisfaction and differing expectations regarding their MDD treatments.

Abstract: Lithium is a lifesaving medication and the gold standard for management of bipolar disorder. It has a narrow therapeutic index, making toxicity an important clinical concern.

Abstract: Functional impairment in schizophrenia results in substantial burden to patients, caregivers, and healthcare systems. Addressing this impairment remains a critical unmet need in treatment.

Abstract: Background: Prescription digital therapeutics (PDTs) are software-based interventions for managing and treating medical conditions prescribed by healthcare providers and dispensed by pharmacists.

Abstract: Objective: ADHD is a chronic and prevalent neurodevelopmental disorder in adults, characterized by symptoms of inattention, hyperactivity, and impulsivity.

Abstract: Background: Clinical data support an association between antipsychotic nonadherence and adverse outcomes in schizophrenia; however, the influence of nonadherence on mortality remains unknown.

Abstract: OBJECTIVE: This post hoc analysis examined the efficacy and safety of aripiprazole lauroxil (AL) every-2-months for the treatment of schizophrenia by baseline severity of illness in the double-blind ALPINE study (NCT03345979).

Abstract: Clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, but it requires careful monitoring due to its narrow therapeutic index and potential for life-threatening toxicity.

Abstract: Objective: The analysis evaluated outcomes following initiation of paliperidone palmitate 1-month (PP1M) vs oral antipsychotics (OAPs) within ?3-years and >3-5-years of a schizophrenia diagnosis.

Abstract: TV-44749 is a once-monthly, subcutaneous, extended-release injectable based on innovative copolymer delivery technology that ensures controlled release of olanzapine, designed to provide sustained efficacy over 1 month without post-injection delirium/sedation syndrome (PDSS) risk.

Abstract: Background: For people with schizophrenia, long-acting injectable antipsychotics (LAIs) can improve adherence and clinical outcomes versus oral antipsychotics, yet remain underused.

Abstract: Background: CT-155/BI 3972080 is an investigational digital therapeutic for treatment of experiential negative symptoms (ENS) of schizophrenia.

Abstract: Background: Negative symptoms of schizophrenia (NS) profoundly impact functional outcomes. As there are currently no approved pharmacotherapies for NS, innovative treatments are needed.

Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.

Abstract: OBJECTIVE: Combination olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain.

Abstract: Objective: To compare the executive functioning (EF) efficacy measure with patient exit interviews in a pediatric population treated with centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor for ADHD.

Abstract: Antipsychotic nonadherence increases the risk of relapse, rehospitalization, and adverse outcomes for patients. Monitoring medication adherence is challenging because patient self-report and caregiver collateral is frequently unreliable.

Abstract: TV-44749 is an innovative, once-monthly, subcutaneous (SC) long-acting injectable (LAI) olanzapine.

Abstract: Non-adherence to oral antipsychotics is a barrier to optimal outcomes for patients with schizophrenia. This study aimed to identify treatment patterns and the impact of treatment non-adherence on healthcare resource utilization (HCRU) for patients receiving oral olanzapine.

Abstract: Oral antipsychotic treatments are associated with poor adherence and high disease/healthcare resource utilization (HCRU) burden in patients with schizophrenia. Long-acting injectable (LAI) antipsychotics may improve adherence and reduce HCRU.

Abstract: Introduction: Almost half of US patients with schizophrenia are dual eligibles; however, there is limited understanding of their journey in terms of receipt of long-acting injectable antipsychotic (LAI) treatment, clinical outcomes, and health resource utilization patterns over time.

Abstract: Use of intramuscular (IM) long-acting injectable (LAI) olanzapine is limited due to a boxed warning for post-injection delirium/sedation syndrome (PDSS) and the associated Risk Evaluation and Mitigation Strategy (REMS).

Abstract: Background: Long-acting injectable antipsychotics (LAIs) improve adherence and reduce relapse compared with oral antipsychotics, but LAI use varies.

Abstract: Background:

Abstract: Background:

Abstract: Objective: To analyze subgroup data from a 4-year, open-label study of combined olanzapine and samidorphan (OLZ/SAM) in adults with schizophrenia, schizophreniform disorder, or bipolar I disorder.

Abstract: Background:

Abstract: This is a case involving a 23-year-old male patient with a history of heavy khat use in early childhood, who was diagnosed with bipolar type schizoaffective disorder at the age of 15.

Abstract: Introduction: Experiential negative symptoms (ENS) of schizophrenia include avolition, asociality, and anhedonia, which impact quality of life and functioning. This study assessed the association between social determinants of health (SDOH) and ENS among patients with schizophrenia.

Abstract: Tardive Dyskinesia Impact Scale (TDIS) evaluates TD symptom impact over the previous 7 days and was a KINECTÆ3, KINECTÆ4, and KINECT-PRO outcome.

Abstract: Background: This study described the clinical/demographic characteristics of patients taking antipsychotics/metoclopramide in a long-term care (LTC) setting and treatment patterns for patients with tardive dyskinesia (TD).

Abstract: Background: We previously assessed the multidimensional impact of tardive dyskinesia (TD) on an initial population of individuals (n=286) in the IMPACT-TD Registry. Here, we report results for the full IMPACT-TD Registry cohort at enrollment.

Abstract: Background: We previously assessed patient-reported multidimensional impact of tardive dyskinesia (TD) on an initial set of participants (n=286) in the IMPACT-TD Registry. Here, we present patient-reported outcomes (PROs) for the full IMPACT-TD Registry cohort.

Abstract: Background: Deutetrabenazine is approved by the Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD).

Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and chorea associated with Huntingtonís disease.

Abstract: Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntingtonís chorea. KINECT-PRO is the first study to report the effects of an approved TD medication on the impacts of TD using multiple validated patient-reported outcomes (PROs).

Abstract: Objectives: This review aims to provide an overview of SSRI-induced akathisia, examining its prevalence, underlying mechanisms, and potential role in increasing suicidality.

Abstract: This presentation explores the rates of ADHD being diagnosed, suggesting potential underdiagnosis, particularly in patients presenting with anxiety and depression. These co-occurring conditions are linked to shared factors and the psychological impact of ADHD.

Abstract: Bruxism, a debilitating condition characterized by involuntary teeth grinding, has been increasingly linked to pharmacological treatments, though the underlying mechanisms remain poorly understood.

Abstract: This case examines a 23-year-old male whose cannabis addiction precipitated treatment-resistant psychosis. After one year of heavy use, he developed paranoid delusions (e.g., believing family members were mafia operatives surveilling him).

Abstract: Both pseudocyesis and delusion of pregnancy are so rare that most information on them is found within case reports.

Abstract: Introduction: Immediate-release (IR) oxybates require patients to awaken 2.5 to 4 hours after their first dose for a second dose. Once-nightly sodium oxybate (ON-SXB) is an extended-release formulation, eliminating the need for middle-of-the-night dosing.

Abstract: Burnout among psychiatric clinicians continues to rise due to excessive documentation, administrative demands, and limited time for direct patient care.

Abstract: Burnout among nurses remains a huge problem in the healthcare setting, especially within acute care hospital settings, where long hours, high emotional demands, and complex responsibilities for patient care are prime.

Abstract: Background: It is essential for psychiatrists to build rapport with their patients by engaging in meaningful conversation. However, children with mental health conditions are often reluctant to talk.

Abstract: nurses can be influential leaders working to improve access to care for the over 3.5 million children and adolescents in the United States who need psychiatric care but struggle to access it in traditional healthcare settings.

Abstract: Approximately 70&#37; of individuals with Alzheimerís disease (AD) experience agitation. Current pharmacologic therapies are limited and additional treatments are needed.

While antipsychotic treatment is essential to achieving and maintaining remission in schizophrenia, conventional antipsychotic treatments are associated with numerous shortcomings, including non-adherence, inadequate response, and/or medication-related adverse events.

Bipolar disorder (BD) is a serious mental illness and a notoriously challenging disease for healthcare professionals to accurately diagnose and manage. As a result, high rates of undertreatment and nonadherence generally result in very poor outcomes among these patients.

Tardive dyskinesia (TD), which affects over 500,000 people in the United States (US), is an involuntary movement disorder associated with dopamine-receptor antagonistsñmost commonly antipsychotic drugs.